15 research outputs found
Preliminary investigation of using volatile organic compounds from human expired air, blood and urine for locating entrapped people in earthquakes
Sarcoidosis in residents of northern Israel of Arabic and Jewish origin: a comparative study
Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) andlung cancer survival in the European Prospective Investigation into Cancer andNutrition (EPIC)
Antibodies to cellular antigens in Greek patients with autoimmune rheumatic diseases: anti-Ro(SSA) antibody a possible marker of penicillamine-D intolerance.
Orofacial presentations of sarcoidosis – a case series and review of the literature
Sarcoidosis is a multi-system disease of unknown aetiology characterised by the presence of non-caseating granulomas, the lungs and lymph nodes being the most affected sites. Orofacial manifestations of the condition are increasingly recognised, with several recent case reports where the initial presentation of the disease is in the region. Here, we report six cases of orofacial sarcoidosis which help to illustrate the wide spectrum of the conditio
Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC)
The single-nucleotide polymorphisms (SNPs) rs402710 (5p15.33),
rs16969968 and rs8034191 (15q25.1) have been consistently identified by
genome-wide association studies (GWAS) as significant predictors of lung
cancer risk, while rs4324798 (6p22.1) was previously found to influence
survival time in small-cell lung cancer (SCLC) patients. Using the same
population of one of the original GWAS, we investigated whether the
selected SNPs and 31 others (also identified in GWAS) influence survival
time, assuming an additive model. The effect of each polymorphism on all
cause survival was estimated in 1094 lung cancer patients, and lung
cancer-specific survival in 763 patients, using Cox regression adjusted
for a priori confounders and competing causes of death where
appropriate. Overall, after 1558 person-years of post-diagnostic
follow-up, 874 deaths occurred from all causes, including 690 from lung
cancer. In the lung cancer-specific survival analysis (1102
person-years), only rs7452888 (6q27) and rs2710994 (7p15.3) modified
survival, with adjusted hazard ratios of 1.19 (P = 0.009) and 1.32 (P =
0.011) respectively, taking competing risks into account. Some weak
associations were identified in subgroup analysis for rs16969968 and
rs8034191 (15q25.1) and rs4324798 (6p22.1) and survival in
never-smokers, as well as for rs402710 in current smokers and SCLC
patients. In conclusion, rs402710 (5p15.33), rs16969968 and rs8034191
(both 15q25.1) and rs4324798 (6p22.1) were found to be unrelated to
survival times in this large cohort of lung cancer patients, regardless
of whether the cause of death was from lung cancer or not. However,
rs7452888 (6q27) was identified as a possible candidate SNP to influence
lung cancer survival, while stratified analysis hinted at a possible
role for rs8034191, rs16969968 (15q25.1) and rs4324798 (6p22.1) in
influencing survival time in lung cancer patients who were
never-smokers, based on a small sample
Circulating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort
Normal renal function is essential for vitamin D metabolism, but it is unclear whether circulating vitamin D is associated with risk of renal cell carcinoma (RCC). We assessed whether 25-hydroxyvitamin D3 (25(OH)D3) was associated with risk of RCC and death after RCC diagnosis in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC recruited 385,747 participants with blood samples between 1992 and 2000. The current study included 560 RCC cases, 557 individually matched controls, and 553 additional controls. Circulating 25(OH)D3 was assessed by mass spectrometry. Conditional and unconditional logistic regression models were used to calculate odds ratios and 95% confidence intervals. Death after RCC diagnosis was assessed using Cox proportional hazards models and flexible parametric survival models. A doubling of 25(OH)D3 was associated with 28% lower odds of RCC after adjustment for season of and age at blood collection, sex, and country of recruitment (odds ratio = 0.72, 95% confidence interval: 0.60, 0.86; P = 0.0004). This estimate was attenuated somewhat after additional adjustment for smoking status at baseline, circulating cotinine, body mass index (weight (kg)/height (m)(2)), and alcohol intake (odds ratio = 0.82, 95% confidence interval: 0.68, 0.99; P = 0.038). There was also some indication that both low and high 25(OH)D3 levels were associated with higher risk of death from any cause among RCC cases
Functionally enhanced placenta-derived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves’ ophthalmopathy
The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design
Objective: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. Methods: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. Results: Trial results will be disseminated through peer-reviewed publications and conference presentations. Conclusion: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790). © 2020 Hellenic Society of Cardiolog